Background: There is limited high-quality evidence about the impact of patient navigation (PN) on outcomes for patients with diagnosed cancer.
Introduction
Patient navigation (PN), defined as instrumental and emotional support for patients during diagnosis and treatment for cancer, has been widely promoted as a means for reducing cancer health disparities (1) . Patient navigators identify and address barriers to accessing timely and effective cancer treatment (2) . Findings from randomized controlled trials show that PN improves rates of cancer screening (3) (4) (5) (6) (7) (8) (9) . Most randomized trials of PN for follow-up of abnormal cancer screening show benefit in terms of diagnostic resolution (10) (11) (12) (13) . In contrast, there are limited data about the effectiveness of PN to optimize treatment of patients with diagnosed cancer. In the only published randomized trial of postcancer diagnosis navigation, Ell and colleagues reported no difference in adjuvant treatment adherence and follow-up from telephone navigation compared with written informational materials for low-income women undergoing treatment for breast or gynecologic cancer (14) .
As part of the National Cancer Institute-sponsored Patient Navigation Research Program (PNRP), 2 of the 10 sites conducted patient-level randomized trials of PN among patients with recently diagnosed breast or colorectal cancer. We pooled data from these 2 sites (Denver, CO and Rochester, NY) to examine the hypothesized effect of PN: (i) shorter time to treatment completion; (ii) less psychologic distress; and (iii) greater satisfaction with cancer care. We also expected that patients with inadequate or no insurance, language barriers, lower education, and lower income, would show greater benefit from PN than those with fewer needs.
Materials and Methods
Details about the Rochester protocol have been previously reported (15) . We briefly summarize them along with those from the Denver site.
Setting and study participants
Participants with a definitive diagnosis of breast or colorectal cancer were enrolled in a randomized controlled trial for PN from September 2006 to June 2010 at the 2 study sites. In Rochester, participants were primarily recruited from participating oncology practices (n ¼ 13), both hospital and community based. In Denver, participants were recruited from a single oncology practice within the Denver Health System, an integrated public safety net that includes a hospital and multiple health center sites. Because both sites used similar models for navigation and used the same 3-month outcome measures, we pooled the follow-up data from these 2 sites to increase power.
Participants were eligible to be referred for the trials if they had newly diagnosed breast (female) or colorectal (female or male) cancer and received care from any participating practice. "Newly diagnosed" was defined as within 3 months of diagnosis and not beyond the second cycle of chemotherapy, where relevant. Among patients enrolled after surgery, only patients scheduled for oncology consultation for further treatment, such as chemotherapy and/or radiotherapy, were eligible. We excluded patients who were institutionalized, had dementia, or had a prior cancer (other than nonmelanoma skin cancer), multiple cancers, as well as males with breast cancer. We also excluded individuals who spoke neither English nor Spanish.
The Institutional Review Boards of the University of Rochester, Colorado Multiple Institutional Review Board, and all participating sites approved study procedures. Study participants provided informed consent and completed a HIPAA release form and permission to view and/or obtain medical records.
Randomization
Participants in both Rochester and Denver were individually randomized, stratified by cancer type. In Rochester, stratification also included recruitment site and randomization was done in blocks of 4. An off-site study statistician produced computer generated random numbers and provided randomization assignments in sealed envelopes. Following confirmation of eligibility and informed consent, Research Assistants administered a face-to-face baseline survey to all study patients. They then opened the sealed envelope and notified the participant of their study assignment to receive either PN or usual care.
Intervention
Participants assigned to the intervention arm of the study received care coordination from a patient navigator who acted as a guide and coach during the course of their cancer treatment (15) . Navigators were laypersons from the community who were specifically trained in these tasks. Minimal selection criteria included a high school degree, reliable mode of transportation and a current driver's license. Preference was given to applicants with experience in case management or nonlicensed health professionals. Desirable personal qualities in navigators included strong interpersonal and communication skills, fluency in Spanish and English, showed ability to learn, dependability, initiative, as well as passion for and commitment to improving health care for underserved patients.
Intensive training was provided to navigators locally and nationally at baseline and periodically throughout the course of the project (16) . Navigators were supervised by experienced managers who met with them regularly. A multidisciplinary team was available to provide expert advice and support as needed. Average caseload of each navigator included 20 cancer patients at a given time.
Navigators at both sites followed protocols developed by the PNRP Steering Committee. Navigation began with a baseline assessment that was typically conducted faceto-face at the inception of PN. Navigators and participants collaboratively identified treatment barriers and strategies to address barriers. Common treatment barriers included financial (insurance, copayments, and lost time from work), logistical (transportation, child care), communicational (language, health literacy), and attitudinal (fears and misunderstanding about cancer and its treatment) issues (17) .
Actions taken by the navigator included: supportive contact with the patient, such as face-to-face meetings, telephone, email, or regular mail correspondence; identifying and linking patients to social or financial resources and appropriate community supports; helping with paperwork, obtaining records, scheduling appointments, following-up on test scheduling or results; and accompanying the patient to appointments to help coach as well as providing emotional support (18) . Navigators also provided patients with approved educational materials and promoted treatment adherence, particularly appointment keeping. Navigators helped facilitate coordination of care by ensuring that consultation reports, test results, and information on patients' new prescriptions or prescribed treatments were available to all providers at the time of an appointment. Navigators also encouraged patients to notify practices when they missed a treatment or test or experienced new or changed symptoms, and did so themselves (with patient permission) when the patient failed to do so (19, 20) . Depending on the task and patient preference, follow-up navigation was provided in-person, by phone or other means (e.g., electronic mail). For interested patients, navigators coached patients about how to address their questions with their oncologist and/or other providers. Navigators also collaborated with other members of the oncology team, including assisting patients with scheduling appointments as needed, and following-up on missed appointments.
Data collection
Trained research assistants administered surveys in preferred language (English or Spanish; ref. 21) . Research assistants also abstracted data from medical records.
Demographic measures
Sociodemographic and other measures are shown in Table 1 . Demographic data were obtained from selfreport at the Rochester, NY site and from electronic medical records at the Denver, CO site. (Continued on the following column) Study outcomes measures Time to completion of treatment. Because a major goal of PN is eliminating or reducing delays in care, the time from cancer diagnosis to the end of primary cancer treatment was the primary outcome of this study. Only participants who received radiation and/or chemotherapy were included for this outcome; patients who had no further treatment after surgery were not considered to require navigation. A research assistant abstracted chart data to assess time from diagnosis to end of primary chemotherapy and/or radiation treatment. If a subject received both radiation and chemotherapy, we used time to completion of chemotherapy, which was longer in all but 10 instances. We also conducted a sensitivity analysis for this outcome in which we stratified groups by radiation only, chemotherapy only and both using time based on completion of final treatment.
Psychologic distress. The Impact of events scale (IES) was administered in English or Spanish to assess psychologic distress 3 months following initiation of treatment at both sites (and administered more frequently in Rochester). IES is a psychometrically validated 15-item measure that was developed to assess current distress from life events (22, 23) . Response options for each item range from "0 ¼ not at all" to "5 ¼ often." A total scale score for the IES was calculated by adding all individual items. The total IES score could range from a minimum of 0 to a maximum of 75. Interpretation of the Impact of Events total score ranges from less than 9 (no meaningful impact, subclinical), 9 to 25 (may be affected), 26 to 43 (powerful, certainly affected), to greater than 44 (severe impact, capable of altering ability to function). Because of the skewness of the data toward no distress (coefficient of skewness ¼ 1.69), we created a dichotomous outcome using less than 9 (no meaningful distress) versus 9 or more (potentially meaningful distress). In a sensitivity analysis, we also analyzed the IES as a continuous outcome.
Satisfaction with cancer care. This scale was also administered at both sites at 3 months (and at additional intervals in Rochester) following initiation of treatment. The Patient Satisfaction with Cancer-related Care scale (PSCC) was developed and validated by Jean-Pierre and colleague as part of the PNRP (24) . It is an 18-item measure that assesses patient satisfaction with the cancer care they received. Responses to each item ranged from "1 ¼ not satisfied" to "5 ¼ very satisfied". A total scale score was calculated for the PSCC by adding scores on all individual items. Because the distribution of the responses was strongly skewed toward higher satisfaction (coefficient of skewness ¼ 0.50), we created a dichotomous outcome using the 25th percentile as a cutoff (<75 vs. 75). We also analyzed it as a continuous score to confirm the validity of the dichotomous analysis.
Statistical analysis
We used an intent-to-treat analysis. That is, our analysis was based on initial randomization assignment regardless of receipt or intensity of PN among participants for whom follow-up data were available. We used the F-test from a log-normal regression analysis to assess group-based differences in time to completion of treatment, and k 2 tests for group-based differences in distress and satisfaction. We also completed secondary analyses using stepwise multivariate regression models to assess the effect of PN. We further examined the hypothesis that PN would show greater effects among patients with low income, low education, no insurance, limited English language proficiency, or social isolation by assessing interactions between PN and these factors.
Variance was calculated using the Taylor-series linearization method with study site (Rochester or Denver) as the stratum and practice as the primary sampling unit to account for the clustering of patients within site. A P value of 0.05 or less was considered to be statistically significant. All analyses were conducted using SAS-callable SUDAAN Version 10.0.1 and SAS Version 9.2 on the Windows 7 32-bit platform.
Results
Patient accrual and study flow Figure 1 represents a flow chart of our analytic sample. The Rochester site contributed 319 participants and Denver 119 (27%). There were 353 breast cancer patients (all female) and 85 CRC patients (44 male, 41 female), excluding 1 participant with multiple cancers. Data on time to completion of primary treatment were available for 287 participants, after excluding 151 participants who did not did not require and/or opt for radiation or chemotherapy (many of whom initiated long-term antihormonal treatment). Data on distress and satisfaction were available for 389 and 372 participants, respectively (Fig. 1) .
Participant characteristics
Study participants were predominantly middle aged and older (mean age ¼ 57) females (90%). The present sample included a high proportion of racial-ethnic minority patients (44%), and patients with lower educational attainment (less than or equal to high school, 46%). Some did not have health insurance (18%); fewer did not have English as their primary language (9%). Denver participants were more likely to be Latino or uninsured than participants from Rochester. Baseline characteristics were similar between participants randomized to PN or usual care ( Table 1) .
The majority of participants were diagnosed with breast cancer (80%) because of higher incidence and the presence of designated breast cancer clinics in Rochester that facilitated recruitment. The remainder of the sample (20%) had colorectal cancer. Most participants were diagnosed with stage II or stage III cancer (n ¼ 261). Fifty-six patients received only chemotherapy, 114 received radiation only, and 117 received both treatments.
Time to completion of treatment
A total of 287 participants received chemotherapy or radiation therapy. All completed their treatment. The median time to complete treatment (57 days for intervention and 63 days for control) was not statistically significantly different between the groups (P > 0.05). There were no statistically significant differences when results were stratified by cancer type, stage, or participant characteristics.
Psychologic distress
Participants (n ¼ 389) had a median IES total score of 22.3 with a standard error of 1.83 and a range from 18 to 90. The percentage of each group reporting no appreciable psychologic distress (IES score < 9) did not significantly differ between the 2 groups. Results were unchanged in a logistic regression model.
Irrespective of intervention group assignment, subjects were more likely to report distress if they were female, were younger, had low-income, had part-time employment (vs. full-time or no current employment), or a rented residence (vs. owned or other). In contrast, Hispanic patients reported less distress. Similarly, patients who lived alone were less likely to report distress (Table 2) . Moreover, we observed a statistically significant interaction between navigation and living alone in terms of distress (P < 0.002). Among patients living alone, those assigned to PN were significantly more likely to be distressed.
Satisfaction with cancer care
Among the 372 subjects for whom data were available, the median PSCC score was 81.7 with a standard error of 2.13. In the primary analysis, there was no significant difference in the proportion of PN and control group patients who had a higher satisfaction score (Table 3) . However, we observed significant interactions between treatment group and language (P ¼ 0.04), educational level (P ¼ 0.007), and health insurance (P ¼ 0.006). Specifically, being randomized to navigation was associated with significantly greater likelihood of higher satisfaction with cancer care among participants with lower English proficiency (OR, 3.75; 95% CI, 1.60-8.79), less than a high school education (OR, 2.37; 95% CI, 1.28-4.40), and no health insurance (OR, 2.36; 95% CI, 1.41-3.93).
Sensitivity analyses
We conducted sensitivity analyses to assess the robustness of our findings. We assessed time to completion of treatment using an analysis stratified by treatment type (chemotherapy only, radiation only, and both). We also assessed distress and satisfaction using continuous measures. Although both sites measured distress and satisfaction at 3 months, only Rochester collected these data at baseline and (depending on the length of the patient's treatment) at 6, 9, and 12 months. Using the Rochester data, we assessed the impact of controlling for baseline scores as well as longitudinal changes in these scores. In each case, the results were unchanged, that is, no statistically significant difference between the PN and control groups. Specifically, distress declined from 84% at baseline to 76% at 3-month follow-up among controls and from 90% to 83% among those receiving PN. In contrast, satisfaction declined from 80% at baseline to 71% at 3-month follow-up among controls and from 77% to 72% among those receiving PN.
Discussion
In a randomized controlled trial of PN to reduce barriers to cancer treatment, we observed no overall effect on patients' time to completion of treatment. Within 3 months of treatment initiation, we also found no overall effect on psychologic distress or satisfaction with care. However, subgroup analysis showed benefits for selected patients. In particular, those with educational, language, and insurance barriers reported greater satisfaction when navigated. These findings, if replicated, suggest that PN may improve experience of care among patients with the greatest needs, which conforms to the original intent of PN (25) . The absence of overall benefit from navigation between breast and colorectal cancer patients is consistent with the findings of Ell and colleagues who observed no significant effect on patient adherence to adjuvant treatment from telephone navigation (compared with information materials) for patients with breast or gynecological cancer (14) . However, we observed improved satisfaction among underserved patients, especially among the most vulnerable.
Our findings of no overall benefit contrast with benefits observed in most randomized trials of PN for cancer screening (3) (4) (5) (6) (7) (8) (9) , and diagnostic follow-up on abnormal cancer screening tests (10-13). These seemingly conflicting findings may reflect better targeting of PN when used for screening or follow-up on abnormal screening. When used for those purposes, PN typically targets patients who have failed to receive a particular intervention. That is, eligibility for enrollment is often based on shown need. In contrast, in our trial and the one conducted by Ell and colleagues (14) , navigation was provided to all eligible (intervention group) patients. While both our study populations were socially disadvantaged, we did not specifically target patients who had not adhered to their cancer treatment or who had dropped out of treatment because of various barriers. Greater attention from providers to disadvantaged patients with diagnosed cancer (such as social work services or care coordinators in cancer centers) may explain these findings, and why traditional social risk factors (age, race, ethnicity, education, income, language, or insurance) were not associated with longer time to treatment. In addition, increasing attention to patients' socioeconomic needs at both study sites may have led to more assistance from social work and other institutional resources that may have mitigated the impact of PN.
Our finding of improvement in experience with health care among patients with selected risk factors has plausibility based on our theoretical model for navigation (1) . Navigators were trained to address educational, language, and insurance barriers. Conceivably, addressing these risk factors yielded improved satisfaction with cancer care. The finding that patients living alone experienced greater distress when navigated was unexpected and warrants replication.
These findings come with important limitations. First, we aggregated findings from 2 trials that used the same design and measures to increase our power to detect effects. The 2 sites differed in the frequency of assessment of distress and satisfaction and the 2 study populations differed in rates of no insurance and ethnicity. Thus, we controlled for site effects and also conducted sensitivity analyses that controlled for baseline scores and assessed longer follow-up. In these sensitivity analyses, we observed the same findings. Second, while the positive findings are consistent with our original PNRP secondary hypothesis, they reflect secondary analyses and should be replicated. Third, we examined PN during care for only 2 types of cancer and most of our participants were women with breast cancer. We do not know whether our findings would be generalizable to other cancers. Last, we studied navigation provided in only 2 communities and do not know whether these findings generalize to other parts of the country.
In conclusion, PN during cancer treatment did not affect time to completion of treatment, satisfaction with cancer care, or distress in the overall population. However, selected subgroups may benefit in terms of patient satisfaction. The association of PN with increased distress among those living alone was unexpected and requires further study.
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